Wegovy is one part of a wider weight-management plan.
Semaglutide can help regulate appetite and support weight loss, but treatment works best alongside realistic nutrition, movement, behaviour change and regular clinical review.
Once-weekly prescription weight-loss treatment
Wegovy Injections for Weight Loss
A once-weekly prescription injection that can help reduce hunger, increase fullness and support sustainable weight loss, with clinical guidance at every stage.
Wegovy is used once weekly alongside a reduced-calorie diet and increased physical activity. It is prescribed only after an individual clinical assessment and is not suitable for everyone.
For eligible adults of all genders
One injection each week
Four doses in each FlexTouch pen
Gradual dose escalation
Side-effect and nutrition support
Discreet medication delivery
Quick product facts
Wegovy injections at a glance
-
Active ingredient
Semaglutide
-
Medicine type
GLP-1 receptor agonist
-
How often?
Once weekly
-
Pen duration
Four weekly doses
-
Starting strength
0.25 mg
-
Available strengths
0.25 mg to 2.4 mg, plus 7.2 mg where appropriate
-
Prescription needed?
Yes
-
Who is it for?
Eligible patients after assessment
FlexTouch strengths
Wegovy doses and LIVVE pricing
The usual pathway starts at 0.25 mg and increases gradually to reduce gastrointestinal side effects. Your prescriber may delay escalation if you are not tolerating the current dose. LIVVE is also planning to include the 7.2 mg dose where clinically appropriate and once the pathway, supply and pricing have been confirmed.
| Strength | Usual treatment stage | FlexTouch pen | LIVVE-listed price |
|---|---|---|---|
| 0.25 mg | Week 1–4 Usual starting dose |
One injection weekly × 4 |
£185 |
| 0.5 mg | Weeks 5–8 |
One injection weekly × 4 |
£185 |
| 1 mg | Weeks 9–12 |
One injection weekly × 4 |
£185 |
| 1.7 mg | Weeks 13–16 |
One injection weekly × 4 |
£235 |
| 2.4 mg | From week 17; standard maintenance dose |
One injection weekly × 4 |
£250 |
| 7.2 mg | Additional maintenance option for some adults living with obesity after time on 2.4 mg |
One injection weekly × 4 |
£259 |
About the 7.2 mg dose: Wegovy 7.2 mg is included in current product information as an additional maintenance option for some adult patients with obesity after at least four weeks on 2.4 mg. It is not an automatic next step. LIVVE will only prescribe it where clinically appropriate and once the clinical pathway, supply route and pricing have been confirmed.
Eligibility and clinical assessment
Could Wegovy be suitable for you?
Wegovy may be considered for adults living with obesity, or some adults living with overweight and a weight-related health condition. Eligibility is not based on BMI alone.
LIVVE’s Wegovy service is currently for eligible adults only. Although Wegovy product information includes adolescent use in some circumstances, this page describes LIVVE’s adult weight-management pathway.
-
Weight and health history
Your BMI, waist measurement, previous treatment and weight-related health risks are reviewed.
-
Medical suitability
Your clinician considers diabetes, digestive disease, pancreatitis, gallbladder problems, kidney health and other relevant risks. Tell LIVVE if you have gastroparesis or delayed stomach emptying, as Wegovy may not be suitable if this is severe.
-
Current medicines
Wegovy must not be combined with another GLP-1 medicine. Diabetes medicines may need adjustment.
-
Pregnancy planning
Wegovy is not used during pregnancy or breastfeeding and should be stopped at least two months before a planned pregnancy.
-
Nutrition and eating patterns
We consider whether reduced appetite could make it harder to meet protein, fibre, fluid and micronutrient needs.
-
Your goals
Your plan should prioritise health, function and sustainable progress rather than promise a fixed amount of weight loss.
How Wegovy injectionworks
It helps regulate appetite and fullness.
Semaglutide acts like the naturally occurring GLP-1 hormone, helping the brain regulate appetite and food intake. Many people feel fuller sooner and less hungry between meals.
It also slows stomach emptying, which may support fullness but can contribute to nausea, vomiting, constipation, diarrhoea or indigestion.
Wegovy is not a stimulant and should not remove the need to eat. Regular nourishing meals and adequate fluid remain important.
Dose progression
A staged pathway designed to improve tolerability
The standard schedule increases every four weeks from 0.25 mg to 2.4 mg, but your clinician may pause or slow escalation if side effects are difficult. The 7.2 mg dose is a further maintenance option only for some adults living with obesity and is not an automatic next step.
-
Weeks 1–4
0.25 mg once weekly. Learn the pen technique and monitor appetite, hydration and side effects.
-
Weeks 5–12
Move through 0.5 mg and 1 mg only as prescribed and tolerated.
-
Weeks 13–16
1.7 mg is the final escalation step before standard maintenance.
-
From week 17
2.4 mg is the standard maintenance dose. If clinically appropriate, 7.2 mg may be discussed later as an additional maintenance option after time on 2.4 mg.
Using your pen
Inject once weekly on the same day.
Each standard UK Wegovy FlexTouch pen contains four doses. Attach a new disposable needle for every injection and use only the dose shown on your prescribed pen.
Always follow the leaflet supplied with your own pen. Do not set a dose by counting clicks.
-
Check the correct medicine and strength before every injection.
-
Attach a new needle for every dose.
-
Check the flow only before the first injection from each new pen.
-
Inject under the skin of the abdomen, thigh or upper arm.
-
Rotate the exact injection spot each week.
-
Keep the dose button pressed and count slowly to six after the counter reaches zero.
-
Remove the needle after every injection and place it in a sharps bin.
-
Never share your pen or store it with a needle attached.
Side effects and safety
What you may notice, and when to get help
Digestive side effects are common, especially when treatment starts or the dose increases.
-
Common effects
Nausea, vomiting, diarrhoea, constipation, abdominal pain, indigestion, headache, tiredness, dizziness and injection-site reactions can occur.
-
Contact LIVVE
Ask for advice if symptoms persist, worsen, affect eating or drinking, cause repeated vomiting or make normal activity difficult.
-
Seek urgent help
Get urgent medical advice for severe persistent abdominal pain, serious allergic symptoms, severe dehydration, sudden loss of vision or rapidly worsening eyesight. Also seek urgent advice for severe constipation with stomach pain, bloating, vomiting or inability to pass wind or stool.
Do not increase your dose to overcome a plateau. Severe vomiting or diarrhoea can cause dehydration and affect kidney function. Any dose change must be agreed with your prescriber.
Supporting healthy weight loss
Protect nutrition and muscle while appetite is lower
A good programme is about more than eating as little as possible. LIVVE should help you maintain nourishing intake and build habits that can continue beyond medication.
-
Protein
Include a useful source at meals to support muscle maintenance and recovery.
-
Fibre
Increase gradually with fluid to support bowel health and reduce constipation.
-
Hydration
Drink regularly, especially if nausea, vomiting or diarrhoea reduces intake.
-
Strength and movement
Combine regular movement with resistance exercise where appropriate.
Your LIVVE pathway
How assessment, prescribing and follow-up work
-
Complete your assessment
Share your medical history, medicines, weight history, previous treatment and goals.
-
Clinical review
A LIVVE prescriber checks eligibility, risks, interactions and whether Wegovy is appropriate.
-
Prescription and delivery
If approved, your prescribed strength is dispensed with instructions and discreet delivery.
-
Ongoing support
Reviews cover side effects, appetite, nutrition, weight progress and dose suitability.
Where Wegovy injection fits
Other weight-management options
Your clinician may discuss another treatment if Wegovy injections are unsuitable, unavailable or not meeting your needs.
| Option | Format | How it fits |
|---|---|---|
| Wegovy® injection | Once-weekly semaglutide injection | Standard UK FlexTouch injection pathway. |
| Mounjaro® injection | Once-weekly tirzepatide injection | May be discussed if it better suits your health, preferences or previous treatment. |
| Wegovy® tablets | Oral semaglutide tablet | May be discussed if it better suits your health, preferences or previous treatment. |
Ready to find out whether Wegovy injections are suitable?
Start with a proper clinical assessment. LIVVE will help you understand whether treatment is appropriate, which strength to begin with and how your progress will be supported.
Medical disclaimer: This page is for information only and does not replace individual medical advice. Wegovy is a prescription-only medicine supplied only after assessment and approval by an appropriate prescriber. Eligibility, supply and dose changes are subject to clinical suitability. Always read the patient information leaflet and follow your dispensing label and clinician's instructions.